Newsroom
What the studio has built, cleared, and said.
Announcements, articles, and the annual studio report. Media inquiries go to the address below.
All items
Latest from KaRama.
8 items
Then vs. now: how long an SFDA device pathway actually takes
The received wisdom on Kingdom regulatory timelines is a decade out of date. We pulled the actual clock on four of our own submissions.
Why localization fails at the entity, not the product
Foreign health technology does not lose Kingdom contracts because the technology is wrong. It loses them because the company was never built to be bought from here.
Building an allergy panel for a population imported panels miss
The Gulf's dominant allergens are underrepresented in every commercial panel on the market. Patients test negative and stay undiagnosed. Allergenix starts from the other end.
What a founder's stake means, and what it does not
We take a founder's stake, not a fund's position. The distinction changes who we can be honest with and when.
KaRama Bio places second in the Ministry of Health datathon at GHE 2025
Competing against national research teams on Saudi clinical data. The model behind the entry now sits inside the KaRama Bio product.
KaRama Ltd. named a finalist in the NextGen Pitch Competition
Selected from the Kingdom-wide field on the strength of the studio model rather than any single product.
TwinGuard AI incorporated as the studio's eleventh company
Digital twin modeling for hospital operations, formed with a cluster partner.
KaRama joins Microsoft for Startups
Platform credits and go-to-market support extended across the portfolio.
Media contact
For press inquiries.
Write to KaRamaVS@KaRama.Tech with your outlet, your deadline, and what you need. We respond to dated requests first.
Logos, leadership photography, and portfolio company fact sheets are available on request.